[Primary urothelial carcinoma of the prostate: A case report and review of the literature].

Autor:	Han YF; Department of Urology, Yuebei People`s Hospital Affiliated to Shantou University Medical College, Shaoguan, Guangdong 512026, China., Chen D; Department of Urology, Yuebei People`s Hospital Affiliated to Shantou University Medical College, Shaoguan, Guangdong 512026, China., Peng L; Department of Urology, Yuebei People`s Hospital Affiliated to Shantou University Medical College, Shaoguan, Guangdong 512026, China., Lai B; Department of Urology, Yuebei People`s Hospital Affiliated to Shantou University Medical College, Shaoguan, Guangdong 512026, China., Huang HC; Department of Urology, Yuebei People`s Hospital Affiliated to Shantou University Medical College, Shaoguan, Guangdong 512026, China., Wen XQ; Department of Urology, The Third Hospital of Sun Yat-sen University, Guangzhou, Guangdong 510630, China.
Jazyk:	čínština
Zdroj:	Zhonghua nan ke xue = National journal of andrology [Zhonghua Nan Ke Xue] 2020 Nov; Vol. 26 (11), pp. 1010-1014.
Abstrakt:	Objective: To investigate the clinical diagnosis, treatment and prognosis of primary urothelial carcinoma of the prostate. Methods: We retrospectively analyzed the clinical data on one case of primary urothelial carcinoma of the prostate and reviewed the relevant published literature. Results: The patient, aged 83 years old and diagnosed with primary urothelial carcinoma of the prostate, was treated by neoadjuvant chemotherapy with gemcitabine plus cisplatin preoperatively, injected with 5-fluorouracil into the cutting edge of the tumor intraoperatively, and pathologically confirmed with high-grade invasive primary urothelial carcinoma of the prostate, followed by adjuvant chemotherapy with gemcitabine plus cisplatin. No recurrence or metastasis was observed during 1-year follow-up. Conclusions: Primary urothelial carcinoma of the prostate is rare and highly malignant. If the tumor is localized, the patient needs to be treated by neoadjuvant chemotherapy preoperatively, injection with anti-tumor drugs into the cutting edge of the tumor intraoperatively, and adjuvant chemotherapy and regular follow-up postoperatively.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu